Annoek E. C. Broers

Learn More
Cyclosporine A (CsA) and imatinib are both CYP3A4 and P-glycoprotein substrates. Concomitant use after hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) or Philadelphia chromosome-positive (Ph+) acute lymphatic leukemia (ALL) may therefore result in a pharmacokinetic interaction. Although case reports and a recent small study(More)
Deficient thymopoiesis and retarded recovery of newly developed CD4(+) T cells is one of the most important determinants of impaired immunocompetence after hemopoietic stem cell transplantation. Here we evaluated whether Fms-like tyrosine kinase 3 (Flt3) ligand (FL) alone or combined with IL-7 affects T cell recovery, thymopoiesis, and lymphoid progenitor(More)
BACKGROUND AND OBJECTIVES Interleukin-7 (IL-7) has been studied for its possible immunorestorative capacities following stem cell transplantation and has been shown to enhance post-transplant immune recovery predominantly by peripheral T-cell expansion. A major concern of IL-7 is its possible aggravating effect on graft-versus-host and host-versus-graft(More)
Dear Editor, We thank Dr. A.E. Eskazan for his comment on our recent article on the drug-drug interaction between cyclosporine A (CsA) and imatinib, in which he asked for some important clarifications [1]. The first question raised was why the patients were treated with imatinib after allogeneic hematopoietic stem cell trans-plantation (alloHSCT) instead of(More)
  • 1